The FDA approved AstraZeneca’s baxdrostat, extending access to the company’s adrenal-suppression hypertension approach for certain patients, AstraZeneca said Monday. The approval adds regulatory momentum to a program positioned to support the company’s broader cardiovascular ambitions and portfolio growth plans. The filing underscores regulators’ continued willingness to evaluate mechanism-based blood-pressure therapies beyond established drug classes. Baxdrostat’s differentiation—by targeting a blood-pressure–relevant enzyme pathway—could broaden treatment options for patients who remain inadequately controlled on existing regimens.